| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 158 | 9.800 |
Why?
|
| Antibodies, Bispecific | 6 | 2023 | 27 | 4.300 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2024 | 68 | 3.210 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 627 | 2.500 |
Why?
|
| Mutation | 6 | 2024 | 2404 | 1.850 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 44 | 1.710 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 64 | 1.470 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 75 | 1.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 308 | 1.410 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2024 | 295 | 1.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 393 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 313 | 1.100 |
Why?
|
| Lymphoma, B-Cell | 2 | 2023 | 57 | 1.050 |
Why?
|
| Humans | 52 | 2024 | 57735 | 0.980 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 25 | 0.970 |
Why?
|
| Lymphoma, Follicular | 1 | 2024 | 15 | 0.940 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.920 |
Why?
|
| Leukostasis | 1 | 2023 | 1 | 0.920 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 12 | 0.900 |
Why?
|
| Breast Neoplasms | 10 | 2021 | 1125 | 0.890 |
Why?
|
| Lymphoma | 1 | 2023 | 97 | 0.850 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 200 | 0.830 |
Why?
|
| Hematology | 1 | 2022 | 10 | 0.810 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 17 | 0.790 |
Why?
|
| Eosinophilia | 1 | 2021 | 25 | 0.780 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 50 | 0.780 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 72 | 0.770 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 47 | 0.770 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2020 | 2 | 0.750 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2021 | 61 | 0.750 |
Why?
|
| Myocarditis | 1 | 2021 | 46 | 0.740 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 68 | 0.740 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 38 | 0.740 |
Why?
|
| Kidney Pelvis | 1 | 2020 | 6 | 0.730 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 130 | 0.720 |
Why?
|
| Kidney | 1 | 2021 | 386 | 0.670 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 39 | 0.650 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 5 | 0.640 |
Why?
|
| Bone Marrow Cells | 4 | 2021 | 229 | 0.630 |
Why?
|
| Gap Junctions | 3 | 2012 | 17 | 0.630 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 19 | 0.630 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 30 | 0.620 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 54 | 0.620 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 312 | 0.600 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1132 | 0.600 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 5 | 0.530 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 25 | 0.510 |
Why?
|
| Stromal Cells | 2 | 2012 | 65 | 0.510 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 139 | 0.490 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 84 | 0.490 |
Why?
|
| Lower Extremity | 1 | 2015 | 143 | 0.460 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 1337 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 447 | 0.430 |
Why?
|
| Cell Communication | 2 | 2012 | 130 | 0.430 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2011 | 37 | 0.420 |
Why?
|
| Disease Progression | 3 | 2024 | 937 | 0.410 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 352 | 0.410 |
Why?
|
| Immune Tolerance | 2 | 2011 | 169 | 0.380 |
Why?
|
| Bone Marrow | 2 | 2021 | 173 | 0.350 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 46 | 0.350 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2012 | 193 | 0.350 |
Why?
|
| Repressor Proteins | 3 | 2024 | 335 | 0.350 |
Why?
|
| Female | 18 | 2024 | 29972 | 0.340 |
Why?
|
| Cell Transdifferentiation | 2 | 2009 | 11 | 0.330 |
Why?
|
| Neoplasms | 4 | 2024 | 1181 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 859 | 0.320 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 65 | 0.300 |
Why?
|
| Regeneration | 1 | 2008 | 88 | 0.290 |
Why?
|
| Aged | 4 | 2024 | 12858 | 0.290 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 20 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2024 | 121 | 0.260 |
Why?
|
| Adult | 7 | 2024 | 15330 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 173 | 0.240 |
Why?
|
| Middle Aged | 5 | 2024 | 15723 | 0.240 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 114 | 0.240 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.230 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 226 | 0.230 |
Why?
|
| Carboplatin | 2 | 2015 | 39 | 0.230 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.230 |
Why?
|
| Cell Line, Tumor | 6 | 2015 | 1333 | 0.230 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 4951 | 0.230 |
Why?
|
| Tissue Donors | 1 | 2024 | 128 | 0.230 |
Why?
|
| Coculture Techniques | 3 | 2012 | 90 | 0.230 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.230 |
Why?
|
| Phenylurea Compounds | 1 | 2023 | 27 | 0.230 |
Why?
|
| Benzothiazoles | 1 | 2023 | 17 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 117 | 0.220 |
Why?
|
| Male | 5 | 2024 | 26626 | 0.210 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 17 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 159 | 0.210 |
Why?
|
| Disease Management | 1 | 2024 | 207 | 0.210 |
Why?
|
| Cell Cycle | 3 | 2015 | 377 | 0.210 |
Why?
|
| Mice | 6 | 2021 | 10087 | 0.210 |
Why?
|
| MicroRNAs | 4 | 2012 | 617 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 315 | 0.200 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 18 | 0.200 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 62 | 0.200 |
Why?
|
| Heart | 1 | 2024 | 270 | 0.200 |
Why?
|
| Stem Cell Niche | 1 | 2021 | 11 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 276 | 0.200 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.200 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 12 | 0.190 |
Why?
|
| Genes, p53 | 1 | 2021 | 53 | 0.190 |
Why?
|
| Animals | 11 | 2021 | 19307 | 0.190 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 37 | 0.190 |
Why?
|
| Cell Dedifferentiation | 1 | 2021 | 4 | 0.190 |
Why?
|
| Remission Induction | 1 | 2021 | 135 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 192 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 420 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 38 | 0.180 |
Why?
|
| Prognosis | 2 | 2022 | 1521 | 0.180 |
Why?
|
| Laser Therapy | 1 | 2020 | 34 | 0.180 |
Why?
|
| Abdomen | 1 | 2020 | 88 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2020 | 8 | 0.180 |
Why?
|
| Splenic Neoplasms | 1 | 2020 | 8 | 0.180 |
Why?
|
| Anthracyclines | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cytarabine | 1 | 2020 | 34 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 253 | 0.180 |
Why?
|
| Allografts | 1 | 2020 | 42 | 0.180 |
Why?
|
| Clavicle | 1 | 2019 | 4 | 0.170 |
Why?
|
| Fracture Dislocation | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2021 | 927 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 13 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 414 | 0.170 |
Why?
|
| Fracture Fixation, Internal | 1 | 2019 | 38 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 91 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 309 | 0.160 |
Why?
|
| Phenotype | 2 | 2012 | 1124 | 0.160 |
Why?
|
| Triazines | 1 | 2018 | 20 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2018 | 21 | 0.160 |
Why?
|
| Fractures, Bone | 1 | 2019 | 138 | 0.160 |
Why?
|
| Telemedicine | 1 | 2023 | 309 | 0.150 |
Why?
|
| Chemokine CXCL12 | 2 | 2012 | 14 | 0.130 |
Why?
|
| Malaysia | 1 | 2015 | 2 | 0.130 |
Why?
|
| Trastuzumab | 1 | 2015 | 9 | 0.130 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2015 | 17 | 0.130 |
Why?
|
| Edema | 1 | 2015 | 40 | 0.130 |
Why?
|
| Syndrome | 1 | 2015 | 167 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2015 | 86 | 0.130 |
Why?
|
| Neurons | 2 | 2012 | 846 | 0.120 |
Why?
|
| Fatigue | 1 | 2015 | 100 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 111 | 0.120 |
Why?
|
| Genes, Reporter | 2 | 2012 | 242 | 0.120 |
Why?
|
| Cell Death | 1 | 2015 | 264 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 472 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 173 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 2013 | 7 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 133 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 15 | 0.110 |
Why?
|
| CD24 Antigen | 1 | 2012 | 16 | 0.110 |
Why?
|
| Connexin 43 | 1 | 2012 | 14 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 34 | 0.110 |
Why?
|
| Neurokinin A | 1 | 2012 | 7 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1458 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2012 | 98 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2020 | 762 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 375 | 0.100 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 3 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2012 | 2850 | 0.100 |
Why?
|
| Allergens | 1 | 2011 | 43 | 0.100 |
Why?
|
| Neurogenesis | 1 | 2012 | 59 | 0.100 |
Why?
|
| Tachykinins | 1 | 2011 | 9 | 0.100 |
Why?
|
| Adult Stem Cells | 2 | 2010 | 28 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2020 | 4982 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2013 | 219 | 0.100 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 35 | 0.100 |
Why?
|
| Cell Division | 1 | 2012 | 440 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 16 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 666 | 0.090 |
Why?
|
| Immune System | 1 | 2012 | 129 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2010 | 35 | 0.090 |
Why?
|
| K562 Cells | 1 | 2010 | 58 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 242 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 473 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 140 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 161 | 0.080 |
Why?
|
| Guided Tissue Regeneration | 1 | 2009 | 4 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 213 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 35 | 0.080 |
Why?
|
| Asthma | 1 | 2011 | 397 | 0.070 |
Why?
|
| Immunization | 1 | 2008 | 126 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2012 | 2082 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 67 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 122 | 0.070 |
Why?
|
| United States | 1 | 2020 | 7380 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 225 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2009 | 1282 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 895 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1534 | 0.060 |
Why?
|
| Methyltransferases | 1 | 2024 | 45 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 5799 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 38 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 878 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 4215 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 317 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 69 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 345 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 519 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2012 | 589 | 0.050 |
Why?
|
| Azacitidine | 1 | 2020 | 12 | 0.050 |
Why?
|
| Histones | 1 | 2024 | 460 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 71 | 0.050 |
Why?
|
| Exosomes | 1 | 2021 | 41 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 41 | 0.040 |
Why?
|
| Fracture Healing | 1 | 2019 | 25 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 357 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 779 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 5836 | 0.040 |
Why?
|
| DNA Repair | 1 | 2021 | 231 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 594 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 256 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 870 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2020 | 387 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2311 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 127 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 79 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 239 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 35 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2013 | 15 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 144 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 545 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 176 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 160 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 215 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 44 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2013 | 226 | 0.030 |
Why?
|
| Cats | 1 | 2012 | 79 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 188 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2012 | 256 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 280 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2011 | 20 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 328 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2012 | 71 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 188 | 0.020 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 22 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 60 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 44 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 42 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2011 | 60 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 22 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 839 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 357 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 48 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 148 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 221 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 236 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 166 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 170 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 855 | 0.020 |
Why?
|
| Child | 1 | 2019 | 4181 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 362 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 733 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 869 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 503 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 322 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 104 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1962 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 206 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 274 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2013 | 701 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1541 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 458 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 373 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1132 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 1076 | 0.010 |
Why?
|